BioMed X and Servier Launch AI-Driven Bispecific Antibody Engineering Team in France
核心洞察
BioMed X (搜索) has established its first research team in France, Team ADB, focused on AI-empowered design of bispecific antibodies (搜索) at Servier's Paris-Saclay campus.
The collaboration aims to develop an AI-driven platform integrating structural modeling, machine learning, and experimental validation to advance bispecific antibody engineering.
Bispecific antibodies (搜索) represent a promising therapeutic class capable of engaging two molecular targets simultaneously, but their engineering faces challenges in structural constraints and dual-target interaction predictability.
BioMed X (搜索) has officially launched its first research team at BioMed X France, establishing Team ADB (AI-Empowered Design of Bispecific Antibodies (搜索)) at Servier's Paris-Saclay campus. The collaboration represents a significant milestone in applying artificial intelligence to advance next-generation biologic therapeutics in one of Europe's fastest-growing life science ecosystems.
Strategic Partnership for Bispecific Antibody Innovation
The new research team operates within the XSeed Labs (搜索) incubator on Servier's R&D campus and is hosted at the Spartners facility operated by Servier and BioLabs (搜索). This partnership brings together BioMed X (搜索)'s innovation model with Servier's immuno-oncology (搜索) expertise to tackle one of the most challenging areas in biologic drug development.
Bispecific antibodies (搜索) represent one of the most promising classes of biologic therapeutics, capable of engaging two molecular targets simultaneously and enabling new treatment strategies across oncology (搜索), immunology (搜索), and other complex disease areas. However, their engineering remains challenging due to structural constraints, limited predictability of dual-target interactions, and the need to optimize stability, specificity, and manufacturability.
Leadership and Scientific Vision
Team ADB is led by Dr. Tomabu Adjobimey, an immunologist with extensive experience in host-pathogen interactions and immune system modulation. Dr. Adjobimey holds the academic rank of Associate Professor in Immunology (搜索) and Microbiology at the University of Abomey-Calavi (搜索), Benin, and previously led the Human Immunology Group at the Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn (搜索), Germany.
"Our goal is to develop an AI-driven platform that integrates structural modeling, machine learning, and experimental validation to guide the rational design of bispecific antibodies (搜索)," said Dr. Adjobimey. "By enabling more predictive and structure-aware antibody engineering, this approach could significantly accelerate the discovery of innovative biologic therapeutics addressing major unmet medical needs."
BioMed X France Expansion
BioMed X (搜索) France is led by Dr. Paula Wagner Egea, Managing Director and Site Head, who brings expertise in protein engineering and biotech entrepreneurship. Dr. Wagner Egea has a background in de novo protein design and artificial metalloenzyme engineering, earning her Ph.D. in Biochemistry from the Technical University of Munich (搜索) (TUM) with more than seven years of international R&D experience across Europe and the United States.
"The launch of this XSeed Labs (搜索) team represents an important milestone for BioMed X (搜索) as we establish our presence in France," said Dr. Wagner Egea. "We are creating a unique environment for interdisciplinary innovation at the intersection of artificial intelligence and biomedical research. With Team ADB and our partners at Servier, we are bringing fresh thinking to one of the most exciting frontiers in immuno-oncology (搜索)."
Addressing Engineering Challenges
Dr. Clément Barjon, Research Project Leader, Immuno-Oncology (搜索), Institut de R&D Servier Paris-Saclay, emphasized the clinical significance of the collaboration. "Bispecific antibodies (搜索) have become a defining modality in modern oncology (搜索), enabling precise immune redirection and multi-pathway targeting that can deliver deep clinical responses," he said. "However, they require sophisticated engineering, where selecting and optimally pairing binding domains remains largely empirical and difficult to predict. By partnering with BioMed X (搜索), we aim to systematically tackle this challenge."
Innovation Model and Future Impact
BioMed X (搜索) operates as a leading innovation hub for pharma, bridging the gap between academia and industry through its global network of research institutes at top universities and incubators within pharmaceutical companies. The organization applies principles of design thinking and crowdsourcing to drug discovery and development, identifying key challenges across therapeutic areas and recruiting top academic talent to co-create tailored solutions with pharma partners.
The establishment of Team ADB represents BioMed X (搜索)'s commitment to fostering early-career researchers who perform exploratory research, deliver industry-grade results, and pave the way to next-generation therapies. This collaborative model aims to serve as a vital catalyst for innovation in global health for the benefit of all patients.